^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) + gemcitabine (DNA synthesis inhibitor) + Teysuno (gimeracil/oteracil/tegafur) (Thymidylate synthase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Discordant microsatellite instability findings in two samples from a patient with biliary cancer that responded to pembrolizumab
Published date:
07/25/2023
Excerpt:
In a patient with hilar biliary cancer, MSI was examined in two cancer specimens (forceps biopsy from the biliary stricture and endoscopic ultrasound-guided fine-needle aspiration biopsy [EUS-FNAB] from the adjacent lymph node). We observed discordant results, as high frequency of MSI was found only in the forceps biopsy....The tumor became refractory to gemcitabine, cisplatin, and S-1 but responded well to pembrolizumab.
DOI:
10.1007/s12328-023-01833-7
